Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in St Louis, Missouri

This page shows live ClinicalTrials.gov search results for St Louis, Missouri, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2929
Shown on this page
12
Local exact-city summaries
2652
Based on exact city/state matches in the local index.
Local exact-city recruiting
1383
Live official results below use the broader ClinicalTrials.gov location search.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within St Louis, Missouri. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1–12 of 2,929 matching trials in St Louis, MO.
Live ClinicalTrials.gov results.
The summary panels count exact city/state matches in the stored directory for St Louis, MO. The trial list uses ClinicalTrials.gov location matching when live results are available, which can differ from those local counts. No distance radius is applied; check each official record for its listed facilities. During an upstream outage, the list may use the clearly labeled local fallback.

Top conditions in local exact-city summaries

Breast Cancer 63 Prostate Cancer 49 Multiple Myeloma 38 Colorectal Cancer 37 Acute Myeloid Leukemia 33 Obesity 32

Top sponsors in local exact-city summaries

Washington University School of Medicine 318 National Cancer Institute (NCI) 263 AstraZeneca 78 Alliance for Clinical Trials in Oncology 55 Children's Oncology Group 49 ECOG-ACRIN Cancer Research Group 42

Top therapies in local exact-city summaries

Pembrolizumab 109 Carboplatin 103 Nivolumab 85 Cisplatin 78 Paclitaxel 75 Cyclophosphamide 73

Institutions in St Louis

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 2Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
29 Days to 17 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional

Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults

NCT05763251
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
therapy duration
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
120 Days and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
INCA033989, Best Available Treatment
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
43
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

NCT07282665
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C.difficile vaccine, Saline Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
32,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
142
States / cities
Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07536308
View directory record Official record
Conditions
COVID-19
Interventions
OCU500
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Decatur, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
PF-06821497, Docetaxel, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
70
States / cities
Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Phase 1 Interventional

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCA036978, Standard disease-directed therapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
23
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Phase 3 Interventional

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374
View directory record Official record
Conditions
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Interventions
Nadofaragene Firadenovec
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
55
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Phase 3 Interventional

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

NCT05135091
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network

NCT02450851
View directory record Official record
Conditions
Genetic Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 100 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2099
U.S. locations
33
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
10
States / cities
Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:53 PM EDT
Active, not recruiting Not applicable Interventional

The JenaValve ALIGN-AR LVAD Registry

NCT06594705
View directory record Official record
Conditions
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease, Left Ventricular Dysfunction
Interventions
JenaValve Trilogy Heart Valve System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 10:53 PM EDT